Crosstalk Between Glucagon-like Peptide 1 and Gut Microbiota in Metabolic Diseases

Overview

Journal mBio

Publisher American Society for Microbiology

Specialty Microbiology

Date 2023 Dec 6

PMID 38055342

Authors

Yuan Zeng

Yifan Wu

Qian Zhang

Xinhua Xiao

Affiliations

Soon will be listed here.

Abstract

Gut microbiota exert influence on gastrointestinal mucosal permeability, bile acid metabolism, short-chain fatty acid synthesis, dietary fiber fermentation, and farnesoid X receptor/Takeda G protein-coupled receptor 5 (TGR5) signal transduction. The incretin glucagon-like peptide 1 (GLP-1) is mainly produced by L cells in the gut and regulates postprandial blood glucose. Changes in gut microbiota composition and function have been observed in obesity and type 2 diabetes (T2D). Meanwhile, the function and rhythm of GLP-1 have also been affected in subjects with obesity or T2D. Therefore, it is necessary to discuss the link between the gut microbiome and GLP-1. In this review, we describe the interaction between GLP-1 and the gut microbiota in metabolic diseases. On the one hand, gut microbiota metabolites stimulate GLP-1 secretion, and gut microbiota affect GLP-1 function and rhythm. On the other hand, the mechanism of action of GLP-1 on gut microbiota involves the inflammatory response. Additionally, we discuss the effects and mechanism of various interventions, such as prebiotics, probiotics, antidiabetic drugs, and bariatric surgery, on the crosstalk between gut microbiota and GLP-1. Finally, we stress that gut microbiota can be used as a target for metabolic diseases, and the clinical application of GLP-1 receptor agonists should be individualized.

Citing Articles

Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Messak M, Abdelmageed A, Senbel A, Khattab Y, Mandour Y, Shaker O Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40067438 DOI: 10.1007/s00210-025-03932-3.

Alteration of Gastrointestinal Function and the Ameliorative Effects of Polysaccharides in Tail Suspension Rats.

Zang P, Chen P, Chen J, Sun J, Lan H, Dong H Nutrients. 2025; 17(4).

PMID: 40005052 PMC: 11858084. DOI: 10.3390/nu17040724.

The gut-brain-metabolic axis: exploring the role of microbiota in insulin resistance and cognitive function.

Abildinova G, Benberin V, Vochshenkova T, Afshar A, Mussin N, Kaliyev A Front Microbiol. 2024; 15:1463958.

PMID: 39659426 PMC: 11628546. DOI: 10.3389/fmicb.2024.1463958.

Targeting the Gut Microbiota for Prevention and Management of Type 2 Diabetes.

Donati Zeppa S, Gervasi M, Bartolacci A, Ferrini F, Patti A, Sestili P Nutrients. 2024; 16(22).

PMID: 39599740 PMC: 11597803. DOI: 10.3390/nu16223951.

Associations Among Estrogens, the Gut Microbiome and Osteoporosis.

Kverka M, Stepan J Curr Osteoporos Rep. 2024; 23(1):2.

PMID: 39585466 PMC: 11588883. DOI: 10.1007/s11914-024-00896-w.

References

Kato S, Sato T, Fujita H, Kawatani M, Yamada Y . Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. Sci Rep. 2021; 11(1):9167. PMC: 8080802. DOI: 10.1038/s41598-021-88612-x. View

Lebrun L, Lenaerts K, Kiers D, Pais de Barros J, Le Guern N, Plesnik J . Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion. Cell Rep. 2017; 21(5):1160-1168. DOI: 10.1016/j.celrep.2017.10.008. View

Lin S, Yang X, Long Y, Zhong H, Wang P, Yuan P . Dietary supplementation with modified gut microbiota, bile acid profile and glucose homoeostasis in weaning piglets. Br J Nutr. 2020; 124(8):797-808. DOI: 10.1017/S0007114520001774. View

Zhang Q, Xiao X, Zheng J, Li M, Yu M, Ping F . Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats. Exp Biol Med (Maywood). 2017; 243(1):34-44. PMC: 5788162. DOI: 10.1177/1535370217743765. View

Chen L, Fan Z, Wang H, Wen D, Zhang S . Effect of polysaccharides from adlay seed on anti-diabetic and gut microbiota. Food Funct. 2019; 10(7):4372-4380. DOI: 10.1039/c9fo00406h. View

Simon M, Strassburger K, Nowotny B, Kolb H, Nowotny P, Burkart V . Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diabetes Care. 2015; 38(10):1827-34. DOI: 10.2337/dc14-2690. View

Choi H, Rao M, Chang E . Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism. Nat Rev Gastroenterol Hepatol. 2021; 18(10):679-689. PMC: 8521648. DOI: 10.1038/s41575-021-00452-2. View

Dao T, Waget A, Klopp P, Serino M, Vachoux C, Pechere L . Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One. 2011; 6(6):e20700. PMC: 3108962. DOI: 10.1371/journal.pone.0020700. View

Verhoef S, Meyer D, Westerterp K . Effects of oligofructose on appetite profile, glucagon-like peptide 1 and peptide YY3-36 concentrations and energy intake. Br J Nutr. 2011; 106(11):1757-62. DOI: 10.1017/S0007114511002194. View

10.

Napolitano A, Miller S, Nicholls A, Baker D, Van Horn S, Thomas E . Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014; 9(7):e100778. PMC: 4079657. DOI: 10.1371/journal.pone.0100778. View

11.

Marra A, Hanson M, Kondo S, Erkosar B, Lemaitre B . Antimicrobial Peptides and Lysozymes Regulate Gut Microbiota Composition and Abundance. mBio. 2021; 12(4):e0082421. PMC: 8406169. DOI: 10.1128/mBio.00824-21. View

12.

Turnbaugh P, Ley R, Mahowald M, Magrini V, Mardis E, Gordon J . An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027-31. DOI: 10.1038/nature05414. View

13.

Zhang M, Feng R, Yang M, Qian C, Wang Z, Liu W . Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats. BMJ Open Diabetes Res Care. 2019; 7(1):e000717. PMC: 6777410. DOI: 10.1136/bmjdrc-2019-000717. View

14.

Ryan P, Patterson E, Carafa I, Mandal R, Wishart D, Dinan T . Metformin and Dipeptidyl Peptidase-4 Inhibitor Differentially Modulate the Intestinal Microbiota and Plasma Metabolome of Metabolically Dysfunctional Mice. Can J Diabetes. 2019; 44(2):146-155.e2. DOI: 10.1016/j.jcjd.2019.05.008. View

15.

Ren M, Zhang H, Qi J, Hu A, Jiang Q, Hou Y . An Almond-Based Low Carbohydrate Diet Improves Depression and Glycometabolism in Patients with Type 2 Diabetes through Modulating Gut Microbiota and GLP-1: A Randomized Controlled Trial. Nutrients. 2020; 12(10). PMC: 7601479. DOI: 10.3390/nu12103036. View

16.

Smits M, Fluitman K, Herrema H, Davids M, Kramer M, Groen A . Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. Diabetes Metab. 2021; 47(5):101223. DOI: 10.1016/j.diabet.2021.101223. View

17.

Bodinham C, Smith L, Thomas E, Bell J, Swann J, Costabile A . Efficacy of increased resistant starch consumption in human type 2 diabetes. Endocr Connect. 2014; 3(2):75-84. PMC: 3987287. DOI: 10.1530/EC-14-0036. View

18.

Ren H, Tang Q, Yan L, Xia H, Luo H . Evodiamine inhibits gastrointestinal motility via CCK and CCK1 receptor in water-avoidence stress rat model. Life Sci. 2018; 209:210-216. DOI: 10.1016/j.lfs.2018.08.003. View

19.

. The Integrative Human Microbiome Project. Nature. 2019; 569(7758):641-648. PMC: 6784865. DOI: 10.1038/s41586-019-1238-8. View

20.

Kekkonen R, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S . Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World J Gastroenterol. 2008; 14(13):2029-36. PMC: 2701523. DOI: 10.3748/wjg.14.2029. View